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Abstract
Background: Persistent symptoms after treatment of neuroborreliosis (NB) are well-documented, although the
causative mechanisms are mainly unknown. The effect of repeated antibiotic treatment has not been studied in
detail. The aim of this study was to determine whether: (1) persistent symptoms improve with doxycycline
treatment; (2) doxycycline has an influence on systemic cytokine responses, and; (3) improvement of symptoms
could be due to doxycycline-mediated immunomodulation.
Methods/Design: 15 NB patients with persistent symptoms ≥6 months post-treatment were double-blindly
randomized to receive 200 mg of doxycycline or a placebo for three weeks. After a six-week wash-out period, a
cross-over with a three-week course of a placebo or doxycycline was conducted. The primary outcome measures
were improvement of persistent symptoms assessed by neurological examinations, a symptom severity score and
estimation of the quality of life. The secondary outcome measure was changes in systemic cytokine responses.
Results: All 15 patients finished the study. No doxycycline-mediated improvement of post-treatment symptoms or
quality of life was observed. Nor could any doxycycline-mediated changes in systemic cytokine responses be
detected. The study was completed without any serious adverse events.
Discussion: No doxycycline-mediated improvement of post-treatment symptoms or quality of life was observed.
Nor could any doxycycline-mediated changes in systemic cytokine responses be detected. The study was
completed without any serious adverse events. To conclude, in this pilot study, doxycycline-treatment did not lead
to any improvement of either the persistent symptoms or quality of life in post-NB patients. Accordingly,
doxycycline does not seem to be the optimal treatment of diverse persistent symptoms post-NB. However, the
results need to be confirmed in larger studies.
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Background
Neuroborreliosis (NB), caused by the tick-borne spiro-
chete Borrelia (B.) burgdorferi, is the most common form
of disseminated Lyme borreliosis (LB) in Sweden [1] and
Europe [2]. The clinical outcome after antibiotic treat-
ment is fairly good [3,4]. Nevertheless, some patients
have persistent symptoms post-treatment [5-9], which
may include fatigue, myalgia, arthralgia, persistent facial
palsy, sensory disturbances and neurocognitive dysfunc-
tions. This phenomenon, whose pathogenesis is un-
known, constitutes a challenge for the health care system,
since clear diagnostic criteria are lacking [10], the symp-
toms do not correspond with objective measures of ner-
vous system disease [11,12] or with laboratory measures
indicating inflammation [13-15]. Hitherto, there is no
evidence for a persistent B. burgdorferi infection [14,16],
nor has resistance to recommended antibiotics been
demonstrated in vitro [17]. A number of patients report
temporary improvement of the persistent symptoms
while receiving repeated treatment with doxycycline, but
the symptoms tend to return a short time after end of
treatment. Interestingly, in a recent review, Fallon [18]
proposed that the persistent symptoms might be
explained by an ongoing cytokine response, without in-
fection, in the central nervous system (CNS). In fact, pro-
inflammatory cytokines such as interleukin (IL)-6 and
tumor necrosis factor (TNF), which contribute to the in-
flammatory process in the CNS during NB [19,20], have
been experimentally shown to be involved in cognitive
processes in the CNS [21]. In addition, an association be-
tween neuropsychiatric symptoms and prolonged cyto-
kine stimulation has been demonstrated with IL-2 and
interferon (IFN)-α [22]. Furthermore, previous studies by
others and us have shown an inflammatory, T helper 1-
type immune response both in the blood [23-25] and in
the cerebrospinal fluid (CSF) [26-28] in NB patients. This
immune reactivity could be altered by antibiotics, which
apart from their anti-bacterial effects, are known to have
anti-inflammatory properties [29]. Indeed, doxycycline
has been shown to reduce the production of several pro-
inflammatory cytokines, such as TNF, IL-6 and IL-8 in
human monocytes, stimulated with B. burgdorferi [30].
Tetracyclines have also been shown to have neuroprotec-
tive properties both in in vitro and in vivo models of
stroke [31,32] and in multiple sclerosis (MS) [33].
Since antibiotics have several side effects, it is import-
ant to elucidate, in a placebo-controlled manner, the
relevance of a possible immunomodulating impact of
doxycycline on the residual symptoms post-NB. To our
knowledge, this issue has not been studied before. The
aim of this hypothesis-driven, prospective study was to
determine whether doxycycline has an impact on per-
sistent symptoms post-NB, possibly through alterations
in systemic immune responses.
Methods/Design
Participants
Eligible participants were patients with age 18–85 years
with a history of NB; diagnosed according to the Euro-
pean guidelines [34], with persistent symptoms ≥6 months
post-treatment, such as fatigue, facial palsy, headache,
radiculitis and cognitive and neurological dysfunctions.
The exclusion criteria consisted of systemic immunosup-
pression (corticosteroids or other immunosuppressive
drugs), a current infection or ongoing antibiotic treat-
ment, allergy to doxycycline, pregnancy, lactation, psychi-
atric disorders, multiple sclerosis, rheumatoid arthritis,
diabetes mellitus type I or II, systemic inflammatory dis-
eases, liver or kidney dysfunction, current malignancy
and treatment with Didanosine, Quinapril or antacids.
Study design and settings
We conducted a prospective, randomized, double-blind
clinical trial with a cross-over design. The trial was con-
ducted at the Clinic of Infectious Diseases, University
Hospital, Linköping, Sweden, and the immunological
assays were performed at the Unit for Autoimmunity
and Immune Regulation (AIR), Division of Clinical Im-
munology, the Faculty of Health Sciences, Linköping
University, Sweden. The trial started in February 2005
and was completed in February 2008.
Interventions
At the first visit, the participants underwent a neuro-
logical examination according to the study protocol.
Prior to treatment, the persistent symptoms were
defined and their severity score assessed according to a
10-graded symptom severity score (SSS), and the quality
of life (QOL) was estimated using a Swedish version of
the standardized and evaluated short-form health survey
(SF-36) [35]. Furthermore, blood samples were drawn
for analysis of cytokine responses. The patients were
randomized in a double-blind, cross-over fashion to re-
ceive either doxycycline (2 capsules á 100 mg doxycyc-
line monohydrate) or a placebo (2 capsules á 100 mg of
cellulosum microcristallinum), once daily, for three
weeks. The placebo was matched to the study drug with
respect to taste, color and appearance. The persistent
symptoms were assessed, using the SSS, every day dur-
ing treatment. After 5 days of treatment, blood samples
were drawn for analysis of cytokine responses. At the
end of each treatment set, new blood samples were
drawn, neurological examinations were carried out and
the QOL was estimated (Figure 1). The two treatment
sets were separated by a six-week wash-out period, dur-
ing which time no assessments or examinations were
carried out.
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Neurological examinations
The neurological examinations were carried out accord-
ing to a protocol, by one of the two investigators (JS or
PF), before start of and at the end of doxycycline and
placebo treatment, respectively. The examination proto-
col contained the following parts: evaluation of neck
stiffness, the finger-nose test, Romberg’s test, Grasset’s
sign, walking on the heels and toes, assessment of eye
movements, evaluation of nystagmus and cranial nerve
function (especially the facial nerve), sensory examin-
ation, deep tendon reflexes, the Babinski plantar re-
sponse, muscle strength in the extremities, and
fundoscopy. The outcome of the different examinations
was numerically defined as deviant (=2), if one or more
of the neurological examination parts were abnormal,
otherwise as normal (=1). The difference (+, -, 0) be-
tween the outcome of the examination after and before
treatment with doxycycline and placebo was calculated
and used for comparison.
Assessment of symptom severity
At the first visit to the doctor, the patient’s symptoms
were defined and assessed by the patient and the numer-
ical severity level written in a form according to a 10-
graded symptom severity score (SSS): 0 = no symptoms,
1–2 =mild, 3–4 =mild-moderate, 5–6 =moderate, 7–
8 = severe, and 9–10 = unbearable symptoms. The symp-
toms were assessed at the same time every day during
the three-week course of treatment with doxycycline and
placebo, respectively. The difference between the SSS
after and before the start of treatment was calculated for
the symptoms with the two highest SSS (symptom 1 and
2, Table 1) and used for statistical comparison.
Estimation of the quality of life
The estimated QOL was assessed according to the stan-
dardized Swedish version of the SF-36 health survey
(IQOLA SF-36 Standard Swedish Version 1.0) [35] be-
fore the start of and after doxycycline and placebo treat-
ment. The SF-36 includes eight subscales that measure
physical functioning, physical limitations on usual role-
related activities, bodily pain, general health perceptions,
vitality, social functioning, emotional limitations on
usual role-related activities, and mental health. The sub-
scales constitute the basis for calculation of the sum-
mary scores of the mental (MCS) and physical (PCS)
components of the SF-36 [36] (IQOLA SF-36 v.1, the
HRQL-group, Section of healthcare research, University
of Gothenburg and Sahlgrenska University Hospital,
Gothenburg, Sweden). The scores range from 0 (worst)
to 100 (best). The difference between the summary
scores after and before the start of doxycycline and pla-
cebo treatment was used for statistical comparison.
Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from heparinized peripheral blood using density
gradient centrifugation on Lymphoprep (Medinor AB,
Stockholm, Sweden), as previously described by Boyum
[37]. The cells were re-suspended in tissue culture
medium (TCM), as described by Forsberg et al.. [38], to
a final concentration of 1 × 106 PBMC/ml.
Cytokine responses detected by the ELISPOT assay
The enzyme-linked immunospot (ELISPOT) assay, as
previously described [39], was used for analysis of un-


































Figure 1 Overview of the study interventions. The four boxes illustrate the visits to the doctor, and the content in the boxes include the
different outcome measures. At visit 1, the patients were randomly and double-blindly assigned to receive either doxycycline or a placebo
treatment during 3 weeks. At the third visit, the patients received the opposite study drug, in a cross-over manner. The vertical black arrows
indicate time points of blood sampling for analysis of cytokine responses in blood (at the start of, after 5 days, and at the end of treatment,
respectively). During the six-week wash-out period, no assessments or examinations were carried out. Abbreviations: SSS, symptom severity score;
SF-36, Short Form-36..
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Symptoms at study inclusion
1 F 48 4 300 Doxycycline, Ceftriaxone 1 (33) Placebo, Doxycycline 82 Headache, myalgia, arthralgia, concentration and memory
difficulties, depression, insomnia**
2 M 60 7 170 Doxycycline 2 (30) Doxycycline, Placebo 25 Fatigue (1), muscle weakness (2), headache, arthralgia, insomnia
3 M 38 8 20 Doxycycline 12 (0.5) Doxycycline, Placebo 57 Paresthesia, sound sensitivity, imbalance, depression**
4 M 70 2 560 Doxycycline, Ceftriaxone 10 (2.0) Doxycycline, Placebo 87 Hearing loss (1), discomfort of facial palsy (2), arthralgia, myalgia
5 F 59 7 570 Doxycycline, Ceftriaxone 0.75 (100) Placebo, Doxycycline 51 Neck pain (1), imbalance (2), paresthesia, headache
6 F 54 3 850 Ceftriaxone 1 (20) Doxycycline, Placebo 27 Hyperesthesia (1), eye twitching (2)
7 F 60 3 500 Doxycycline, Ceftriaxone 2 (8.0) Placebo, Doxycycline 75 Hearing loss (1), imbalance (2), headache, hypoesthesia
8 M 44 3 N.A♯ Doxycycline, Ceftriaxone 8 (3.0) Placebo, Doxycycline 102 Arthralgia (1), insomnia (2), headache, discomfort of
facial palsy, paresthesia, muscle weakness, concentration
and memory difficulties, depression
9 M 64 12 0.7♯♯ Doxycycline N.A Placebo, Doxycycline 11 Imbalance (1)
10 F 73 5 200 Doxycycline N.A Doxycycline, Placebo 13 Headache (1), fatigue (2)
11 M 65 13 190 Doxycycline, Ceftriaxone 0.5 (30) Doxycycline, Placebo 11 Paresthesia (1), neck pain (2), headache, myalgia,
concentration difficulties, irritability
12 M 82 3 130 Doxycycline N.A Placebo, Doxycycline 11 Imbalance (1), back pain (2), headache, hearing loss, myalgia
13 M 48 4 200 Doxycycline 5 (3.0) Doxycycline, Placebo 24 Dysestesia (1), fatigue (2), headache, hearing loss,
myalgia, concentration and memory difficulties
14 M 50 3 220 Doxycycline N.A Doxycycline, Placebo 16 Paresthesia (1), pain in extremity/radiculitis (2)
15 F 71 3 11* Doxycycline N.A Placebo, Doxycycline 13 Discomfort of bilateral facial palsy (1), paresthesia (2)
The persistent symptoms include all the declared symptoms at inclusion, of which the ones in bold with numbers in parenthesis indicate the two symptoms with the highest symptom severity scores. F, female; M,
male; No, number; CSF, cerebrospinal fluid; NB, neuroborreliosis; LP, lumbar puncture; N.A, not analyzed; ♯Only the intrathecal anti-borrelia antibody index was analyzed. ♯♯ LP was done one week after initiation of



















secretion in PBMC, using the following antigens: an outer
surface protein–enriched fraction (OF) of B. garinii strain
Ip90 (10 μg/ml), as previously described [40] and an
influenza-vaccine ([INFL], 2002/2003, dilution 1:1000,
batch: W6287-2, SBL Vaccine Distribution, Stockholm,
Sweden), used as reference antigens for recall responses
and phytohemagglutinin ([PHA] 20 μg/ml, Sigma Aldrich,
MO, USA), used as a positive control. In short, the ELI-
SPOT plates were coated with monoclonal antibodies,
mouse anti-human IL-4, IL-12p70, IFN-γ (Mabtech AB,
Stockholm, Sweden) and transforming growth factor
(TGF)-β (R&D Systems, MN, USA), diluted with sterile
phosphate buffered saline ([PBS], Medicago AB, Uppsala,
Sweden) to a final concentration of 15 μg/ml. The plates
were incubated overnight at 4°C and frozen at −20°C for
a maximum of 3 months. At analysis, the plates were
thawed at room temperature (RT), unspecific binding
sites were blocked with TCM followed by addition of
100 000 PBMC/well. Thereafter, either TCM (spontan-
eous secretion) or OF was added to the wells in triplicate,
and INFL or PHA in duplicate. TCM was used as a nega-
tive control. The cells were cultured undisturbed for 48 h
at 37°C, 5% CO2 with 95% humidity. Developing of spots,
representing cytokine secreting cells, was conducted with
matched biotin-conjugated monoclonal antibodies, mouse
anti-human IL-4, IL-12p70, IFN-γ (Mabtech AB) and
TGF-β (R&D Systems), diluted in PBS-Tween (Medicago
AB, Uppsala, Sweden) to 1 μg/ml. After incubation in a
dark humidity chamber at RT, alkaline phosphatase-
conjugated streptavidin, diluted 1:1000 in PBS-Tween,
was added. The final step included addition of nitro blue
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate,
diluted in alkaline phosphatase (AP)-buffer (AP conjugate
substrate kit, Bio-Rad, Hercules, CA, USA). The spots
were counted with the AID EliSpot Reader System (soft-
ware version 3.2.2, Germany). One spot was equivalent to
one cytokine-secreting cell per 100 000 lymphocytes. The
median of the triplicates was used for analysis of the
number of cytokine secreting cells. To determine the OF-
specific secretion, the number of spots in the unstimu-
lated wells was subtracted from the number in the OF-
stimulated wells. The OF-specific secretion of IFN-γ and
IL-4 was positive for values >15 spots/100 000 cells and
>10 spots/100 000 cells, respectively, according to previ-
ous results [41].
Antigen-stimulation of peripheral blood mononuclear
cells
PBMC, suspended in TCM to a concentration of 1 × 106
cells/ml, were incubated for 48 h at 37°C, 5% CO2 with
95% humidity, with 1 ml of either lipopolysaccharide
([LPS], from E. coli 026:B6, Lot nr: 123 K4021, 0.2 μg/
ml, Sigma Aldrich, MO, USA), PHA (20 μg/ml, Sigma
Aldrich) or OF (10 μg/ml); all diluted with TCM. PBMC
incubated with merely TCM were used for analysis of
spontaneous cytokine secretion. After incubation, the
cells were centrifuged at RT, 500× g for 10 min. The cell
supernatants were stored at −70°C.
Analysis of cytokine levels in serum and in cell
supernatants
Levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, gran-
ulocyte macrophage colony stimulating factor (GM-
CSF), IFN-γ and TNF were analyzed in serum using a
Human Ultrasensitive Cytokine 10-plex kit (LHC6004,
Invitrogen, CA, USA), according to the manufacturer’s
instructions. All cytokines were analyzed undiluted.
Levels of IL-6 and IL-8 in PBMC supernatants were ana-
lyzed using single-bead kits (LHC0061 and LHC0081,
Invitrogen), whereas a six-plex kit was used (with an
extracellular protein buffer reagent kit [LHB0001], Invi-
trogen) for detection of IL-1β (LHC0011), IL-4
(LHC0041), IL-10 (LHC0101), IFN-γ (LHC4031), GM-
CSF (LHC2011) and TNF (LHC3011, all from Invitro-
gen) in the cell supernatants. Both IL-6 and IL-8 were
diluted 1:100, whereas the other cytokines were analyzed
undiluted. StarStation v.3.0 (Applied Cytometry, Shef-
field, UK) was used for data acquisition and analysis.
Values below the lowest value of the standard curve were
assigned half the value of the lowest standard point.
Outcomes
The primary endpoints were a statistically significant
doxycycline-mediated improvement of the persistent
symptoms, with respect to; a) the neurological examina-
tions, b) the assessment of symptom severity, and/or; c)
the estimated QOL. The secondary endpoint was a sta-
tistically significant doxycycline-mediated effect on sys-
temic cytokine responses.
Sample size
Twenty-four patients, who were previously examined
and treated for well-diagnosed NB at the Clinic for In-
fectious Diseases in Linköping and of whom several had
a continued follow-up at the clinic, were initially identi-
fied during autumn 2004, through screening of the en-
tire catchment-area in the County of Östergötland, and
were asked by phone to participate in the study. Nine of
them were excluded prior to the randomization, whereof
three were without current symptoms and six declined
to participate due to reasons that went together with the
study arrangement (Figure 2).
Randomization
Independent pharmacists at the Pharmacy’s Production
and Laboratories (Stockholm, Sweden) created a com-
puter-generated, anonymous randomization schedule for
all participants, and they manufactured the study drugs.
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The drug bottles were consecutively numbered for each
patient, according to the schedule. Each patient was
assigned a number by one of the two clinical investiga-
tors (JS or PF), and received the drug by the responsible
research nurse, who was delegated the responsibility for
storage and administration of the study drugs. The
randomization code, which was stored in a locked closet
at the Pharmacy of Linköping University Hospital, was
kept undisclosed in a sealed envelope throughout the
study. The code was broken only when the study was
finished and all raw data had been compiled and saved
in locked data files.
Ethics
The study was approved by the Regional Ethical Review
Board at Linköping University, Sweden. Written
informed consent was obtained from all the participants.
Regular inspections were performed by an independent
monitoring group (the TEKLA-group) at the University
Hospital, Linköping. Good clinical and laboratory prac-
tice were applied throughout the study.
Statistical methods
Since data were in general not normally distributed,
non-parametric tests were used for the statistical calcu-
lations. The Wilcoxon rank sum test was used for calcu-
lation of intra-individual differences in change of
neurological examinations with doxycycline and placebo
treatment, respectively, whereas the Mann Whitney U
test was used for a corresponding comparison between
the treatment groups. The Wilcoxon rank sum test was
also used for analysis of intra-individual differences in
change of the two symptoms with the highest SSS, the
PCS and MCS scores and of cytokine responses during
doxycycline and placebo treatment, whereas Mann
Whitney U test was used for corresponding comparisons
between the two groups. As a precaution, a parametric
test (ANOVA) was also used, without finding any signifi-
cant differences in cytokine responses between the two
groups. Statistical calculations were made with the
PASW Statistics 18 software for Microsoft (SPSS Inc.,
Chicago, IL, USA). Graphs were made with GraphPad
Prism, version 5.02 for Microsoft (GraphPad Software
Assessed for eligibility (n=24)
Randomized (n=15)
Allocated to Doxycycline (n=8)
Received Doxycycline (n=8)
Allocated to Placebo (n=7)
Received Placebo (n=7)
Lost to follow-up (n=0)
Discontinued treatment (n=0)
Excluded (n=9):








Allocated to Placebo (n=8)
Received Placebo (n=8)





Figure 2 The study flow chart. Abbreviations: n, number..
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15 patients (6 women, 9 men) with a history of NB were
included in the study. The mean age was 59 years (range
38–82). The median pre-treatment symptom duration
was 4 weeks (range 2–13) and the median CSF cell
count at the time of diagnosis of NB was 200 × 106 leu-
cocytes/L (range 0.7–850), of which a majority were
mononuclear cells. Various persistent symptoms were
reported, although most of the patients had headache,
fatigue, sensory disturbances, arthralgia and myalgia. All
15 patients fulfilled the criteria for post-Lyme disease
syndrome, as defined by the Infectious Diseases Society
of America [42]. The mean duration of the post-
treatment symptoms was 3.4 years (range 0.9–8.5) at in-
clusion. All the patients had received treatment of NB
with either doxycycline or intravenous ceftriaxone for
10–14 days, according to the Swedish treatment recom-
mendations [43]. A re-lumbar puncture, prior to inclu-
sion, had been done as part of clinical routine in ten of
the patients, with signs of diminished or normal cell
counts in the CSF analysis. However, most of the patients
had been treated with at least one additional course of ei-
ther oral (doxycycline) or intravenous (ceftriaxone) anti-
biotics, due to persistence of the symptoms. At the first
treatment set, eight patients were randomized to receive
doxycycline and seven to receive a placebo, with a cross-
over during the second treatment set (Table 1).
Neurological examinations
In cases of a deviant neurological examination at base-
line or at the follow-ups, the facial nerve, the balance,
the sensibility or tendon reflexes were affected. None of
the patients developed new, objective neurological defi-
cits or experienced worsening of current neurological
signs during the study period. Four patients improved
with regard to Romberg’s test, whereof one improved
during doxycycline-treatment and three during placebo-
treatment (Table 2). Most of the patients had unchanged
outcome on neurological examination throughout the
study (Table 2). No significant changes in neurological
examinations were found either within or between the
doxycycline and placebo group.
Assessment of symptom severity
With doxycycline treatment, four (no. 2, 5, 9, 10) patients
improved with respect to the symptom with the highest
severity score (spt1), whereas one (no. 8) patient improved
with respect to spt1 with placebo-treatment, without any
significant differences between the groups (Table 2). Five
(no. 2, 6, 7, 8, 10) patients improved with doxycycline
treatment with respect to the other one of the two symp-
toms (spt2) with the highest severity scores, whereas four
Table 2 Outcome of the neurological examinations, the symptom severity score and assessment of quality of life with
doxycycline and placebo treatment













1 0 N.A +/+ 0 N.A −/−
2 + +/+ N.A 0 -/0 +/+
3 0 N.A −/+ 0 N.A N.A
4 0 0/0 +/− 0 0/0 N.A
5 0 +/− +/− 0 0/+ 0/+
6 0 0/+ −/− 0 0/0 N.A
7 0 0/+ N.A 0 0/- −/+
8 0 0/+ +/− 0 +/+ −/+
9 0 +/N.A +/+ 0 -/N.A −/+
10 0 +/+ +/+ + 0/+ −/+
11 0 0/0 −/+ + 0/0 −/+
12 0 0/0 −/− 0 0/+ +/−
13 0 -/0 −/+ + -/0 +/−
14 0 0/N.A −/+ 0 0/N.A N.A
15 0 0/0 +/− 0 0/0 +/+
A difference between the results of the examinations and assessments after and before treatment was used for comparison of the outcome of treatment, and was
defined as: +, improvement; 0, unchanged or –, worse. For the SSS, the two symptoms (symptom 1 and 2) with the highest severity scores were chosen for
comparison. No significant differences were found in any of the outcome measures either within or between the doxycycline and placebo treatment groups. no,
number; SSS, symptom severity score; SF-36, Short Form-36; PCS, physical component summary; MCS, mental component summary; N.A, not analyzed.


































Figure 3 The number of OF-specific IFN-γ secreting mononuclear cells/100 000 lymphocytes, detected with the ELISPOT assay, before
and after treatment with Doxycycline and Placebo. The graph illustrates cytokine data from the first nine included patients. The OF-specific
cytokine secretion was obtained by subtracting the number of spots in unstimulated (spontaneous) wells from the number of spots in OF-
stimulated wells, illustrating the Borrelia-specific memory immune response. Values, which represent medians of triplicates, are given as number
of cytokine secreting cells/100 000 lymphocytes. The dotted horizontal line indicates the cut-off (= 15 cells/100 000) for OF-specific IFN-γ
secretion. No significant differences in change of the number of cytokine secreting cells were found either within or between the two treatment
groups. Horizontal lines denote the median. Abbreviations: OF, outer surface protein–enriched fraction of B. garinii strain Ip90; IFN, interferon;
ELISPOT; enzyme-linked immunospot assay..
Table 3 Cytokine levels in serum and in cell supernatants before and after doxycycline and placebo treatment
Cytokine Antigen Doxycycline median pg/ml (Interquartile range) Placebo median pg/ml (Interquartile range) Detectable (%)
Before After Before After
Serum
IL-1β 0.43 (0.13-1.50) 0.60 (0.13-1.10) 0.52 (0.13-0.70) 0.60 (0.13-0.84) 68
IL-6 0.19 (0.19-1.60) 0.19 (0.19-2.70) 0.19 (0.19-2.70) 0.19 (0.19-3.20) 43
IL-8 8.15 (6.0-12.9) 9.78 (7.70-14.3) 10.6 (7.40-14.9) 10.1 (7.90-13.7) 100
GM-CSF 0.75 (0.75-9.85) 0.75 (0.75-9.10) 0.75 (0.75-10.2) 0.75 (0.75-11.5) 40
IL-10 0.15 (0.15-1.80) 0.15 (0.15-1.72) 0.15 (0.15-1.30) 0.15 (0.15-1.97) 45
Supernatants
IL-1β OF 267 (147–416) 276 (178–353) 258 (160–372) 257 (212–325) 100
LPS 373 (297–578) 336 (273–459) 384 (306–464) 376 (272–417) 100
IL-6 OF 8495 (5577–11552) 10018 (7283–11436) 9017 (7893–12936) 10549 (6765–11870) 97
LPS 7457 (5522–9344) 7043 (6173–9401) 7339 (5640–9010) 7129 (6164–8376) 100
IL-8 OF 234726 (182996–353519) 256238 (224077–323425) 264450 (187637–377221) 254926 (343734) 100
LPS 170005 (84896–191690) 158091 (116470–210940) 159121 (119796–175857) 153546 (203419) 100
unstim. 949 (425–3337) 887 (412–2657) 966 (580–2637) 728 (443–1324) 100
TNF OF 49.4 (41.8-72.4) 51.8 (26.9-210) 91.2 (66.7-141) 69.3 (25.8-152) 77
LPS 45.0 (23.8-61.3) 45.4 (31.7-56.4) 36.7 (27.1-57.5) 37.1 (26.4-51.9) 77
IL-10 OF 50.6 (41.8-84.7) 59.3 (48.4-84.7) 64.4 (46.3-100) 67.3 (47.0-86.3) 82
LPS 177 (130–272) 184 (114–259) 201 (154–255) 181 (119–280) 98
The table shows median values for spontaneous cytokine levels in serum and antigen-stimulated (and unstimulated IL-8 levels) cytokine levels in peripheral blood
mononuclear cell supernatants, before and after doxycycline and placebo treatment from all 15 included patients. IL, interleukin; GM-CSF, granulocyte
macrophage colony-stimulating factor; TNF, tumor necrosis factor; OF, outer surface–enriched fraction of B. garinii strain Ip90; LPS, lipopolysaccharide; unstim.,
unstimulated.
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(no. 5, 8, 10, 12) improved with placebo-treatment, with-
out any significant differences between the groups. In all,
two patients got worse regarding one of the symptoms
with doxycycline treatment, and four with placebo treat-
ment (Table 2). However, no significant differences were
found when comparing changes in severity of the two
symptoms within or between the doxycycline and placebo
group.
Estimation of the quality of life
The PCS improved in seven (no. 1, 4, 5, 8, 9, 10, 15)
patients with doxycycline treatment and in four (no. 2,
12, 13, 15) with placebo-treatment (Table 2). The MCS
improved in seven (no. 1, 3, 9, 10, 11, 13, 14) with doxy-
cycline treatment and in eight (no. 2, 5, 7, 8, 9, 10, 11,
15) with placebo-treatment. Six patients (no. 3, 6, 11, 12,
13, 14) got worse in PCS with doxycycline treatment,
and six (no. 1, 7, 8, 9, 10, 11) with placebo. The MCS
got worse in six patients (no. 4, 5, 6, 8, 12, 15) with
doxycycline treatment, and in three (no. 1, 12, 13) with
placebo (Table 2). No significant differences were found
in change of PCS or MCS either within or between the
two treatment groups. Notably, only one patient had un-
changed QOL, during placebo treatment (Table 2). How-
ever, in comparison with the general Swedish population
(matched for mean age) [44], the patients had signifi-
cantly decreased mean PCS at time of inclusion
(p= 0.002).
Cytokine responses detected by the ELISPOT assay
The analysis included data from the first nine patients
(patient number 1–9, Table 1), since the assays of the
last six patients were omitted due to technical problems
related to switch of batch for the micro titer plates. Most
patients had an OF-specific IFN-γ response (Figure 3),
whereas few patients had an OF-specific IL-4 response
(data not shown). Likewise, the number of IL-12p70 and
TGF-β secreting cells was low (data not shown). No sig-
nificant differences were found in either spontaneous or
antigen (OF and INFL)-stimulated IFN-γ, IL-4, IL-12p70
or TGF- β responses within or between the doxycycline
and placebo treatment groups.
Cytokine levels in serum
The median values of the circulating levels of IL-1β, IL-
6, IL-8, IL-10 and GM-CSF in serum before and after
doxycycline and placebo treatment are presented in
Table 3. The median of the levels of IL-2, IL-4, IL-5,
IFN-γ and TNF were low or undetectable (data not
shown). No significant differences in change of the cir-
culating cytokine levels in serum were found either
within or between the doxycycline and placebo treat-
ment groups (data not shown).
Cytokine levels in mononuclear cell supernatants
In general, the concentrations of IL-4, IFN-γ and GM-
CSF were low and detectable only in PHA-stimulated
samples, whereas IL-1β, IL-6, IL-8, IL-10 and TNF were
detectable in most of the OF and LPS-stimulated sam-
ples and, except for IL-8, undetectable in unstimulated
samples. Both LPS- and OF-stimulated levels of IL-1β,
IL-6, IL-8, IL-10 and TNF were high both before and
after treatment with doxycycline and a placebo (Table 3).
However, no significant differences were found in
change of either antigen-stimulated or spontaneous
cytokine levels within or between the doxycycline and
placebo treatment groups.
Safety
No serious adverse events occurred during the study
time. However, during doxycycline treatment, nausea
was reported by four patients and vomiting and abdom-
inal pain by one patient each. One doxycycline-treated
patient (no. 10) suffered from a moderate facial skin ery-
thema at the end of the first treatment set, but she con-
tinued the study without any interruption in the
treatment. During placebo treatment, only one patient
reported an adverse event (abdominal pain).
Discussion
This randomized, hypothesis-driven pilot study could
not demonstrate any significant doxycycline-mediated
improvement of the neurological status, severity of the
persistent symptoms or the QOL in NB patients with
persistent symptoms post-treatment. Nor was any spe-
cific impact of doxycycline on cytokines secreted by
PBMC or on cytokine levels in serum found. Any signifi-
cant placebo effect could neither be demonstrated. Sev-
eral studies have highlighted the occurrence of subjective
complaints after treatment of LB [45-47]. However, the
case definitions often differ, which complicates compari-
son of the results. Many of the reported symptoms are
also common in the general population [48], and have de
facto been shown to occur as frequently in controls with-
out LB [49-51]. In this trial, the study population con-
sisted of well-characterized patients with a history of NB,
and they had received treatment with doxycycline or cef-
triaxone at the time of diagnosis. Treatment failure is un-
likely an explanation to the persistent symptoms, since
both treatment alternatives have been shown to be
equally effective with respect to clinical outcome [52-55].
Moreover, doxycycline has been shown to penetrate well
into the CSF and concentrations above the estimated
minimum inhibitory concentration for B. burgdorferi
are exceeded with a daily dose of 200 mg [56,57]. Interest-
ingly, in a recent Norwegian study on NB, a pre-treatment
symptom duration≥ 6 weeks, a high pre-treatment CSF
cell count and female gender were considered as risk
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factors for development of remaining complaints one year
post-treatment of NB [58]. In our study, five patients had
a pre-treatment symptom duration exceeding 6 weeks and
the median total CSF cell count was even higher than in
the Norwegian study, indicating a strong inflammatory re-
sponse in the CSF.
Most of the patients had an unchanged neurological
status throughout the study, with no significant differ-
ences between the two treatments. Several of the
reported symptoms were of neurocognitive character
and it is possible that even subtle changes in these
symptoms would better have been detected, if validated
neurocognitive or psychiatric tests would have been used
in addition to the SSS. The SSS was designed by the
authors in order to observe changes in symptom severity
during treatment. However, it is not a validated test,
which makes comparison with other reports difficult. A
majority of the patients had unchanged symptom sever-
ity, without any significant differences between the treat-
ment sets.
All included patients had a post-treatment symptom
duration by far exceeding 6 months, with a large range
in duration. The phenomenon of persistent symptoms
post-treatment of LB has in recent years been named
Post-Lyme disease syndrome [15,53,59,60], and a defin-
ition of the inclusion and exclusion criteria has been
proposed by the Infectious Diseases Society of America
[42]. All the 15 patients included in this study fulfilled
these criteria. Most of the patients had been retreated
with another course of antibiotics, without long-standing
improvement of the symptoms. At inclusion, both the
MCS and PCS were decreased in the study population
and the PCS was significantly decreased compared with
the general Swedish population, indicating a reduced
QOL in the study population. Similar results were
obtained in a Norwegian follow-up study of patients pre-
viously treated for NB, in which comparison was made
with matched healthy controls [61]. However, in our
study neither the PCS nor the MCS changed signifi-
cantly during three weeks of doxycycline or placebo
treatment. It is not likely that a longer treatment dur-
ation would have revealed any differences in QOL, since
similar results were obtained in a study of B. burgdor-
feri-seropositive patients with persistent musculoskeletal
and neurocognitive symptoms >6 months after treat-
ment, in which no significant differences in QOL were
observed between patients receiving intravenous Cef-
triaxone for 30 days, followed by oral doxycycline for
60 days and those receiving a placebo [14].
The spontaneous, circulating cytokine levels in serum
were in general low, except for IL-8, which could be
detected in all samples, but without any significant
changes during doxycycline and placebo treatment. A
treatment duration of three weeks was, in accordance
with previous studies [32,62], assumed to be sufficient to
influence systemic cytokine responses, whereby any
doxycycline-mediated changes in cytokine levels could
be detected with the sensitive assays. A significant re-
duction in vascular IL-6 expression and reduced protein
levels of IL-8, IL-13 and GM-CSF have been observed
already after two weeks of doxycycline treatment (50–
300 mg/day) in patients scheduled for aneurysm surgery
[63]. IL-1β, IL-6, IL-8, IL-10 and TNF were all well de-
tectable in antigen-stimulated PBMC-supernatants, but
no significant doxycycline-mediated changes could be
observed. The majority of the patients had a substantial
OF-specific IFN-γ response, which is in line with other
studies [26,38], whereas the number of OF-specific IL-
12p70-, TGF-β- and IL-4-secreting cells was low. From
this study we cannot exclude any doxycycline-mediated
changes in cytokine responses in the CSF. Since cytokine
responses in NB mainly are compartmentalized to the
CSF [39], it would have been relevant to measure cyto-
kine levels in the CSF per se. However, this was not feas-
ible from an ethical point of view.
The strengths of this study are the well-characterized
patients without drop-outs, the randomized, placebo-
controlled, cross-over design with a long wash-out
period between the treatment sets, and several clinical
and immunological evaluations. The limitations include
restrictive exclusion criteria and a time-consuming study
protocol, which made the enrolment of patients difficult,
and consequently the patient number small. For this rea-
son, the results need to be assessed with caution. Fur-
ther, no blood analyses of drug concentrations were
carried out, to assure that the study drugs were taken
according to prescription. However, all the patients were
anxious to participate in the study, they assured that
they followed the prescriptions, and they were aware
that they could disrupt the treatment anytime in con-
sultation with the investigators. More patients reported
adverse events during doxycycline treatment, than dur-
ing treatment with a placebo. Despite this fact, no sig-
nificant differences in the subjective assessments were
found between the two treatments.
The patient, who suffered from a facial erythema at
the end of the doxycycline treatment, was allowed to
continue the study, since the symptoms were judged as
mild to moderate, and they declined rapidly. However,
this side effect might have influenced the further assess-
ments by this patient. Retrospectively, it may be noted
that the subjective assessment of the symptom severity
and QOL were not significantly affected by that event.
Conclusions
In this pilot study, we could not demonstrate any
doxycycline-mediated improvement of neither post-
treatment symptom severity nor QOL in patients with
Sjöwall et al. BMC Infectious Diseases 2012, 12:186 Page 10 of 12
http://www.biomedcentral.com/1471-2334/12/186
persistent symptoms after adequate antibiotic treatment
of NB or any evidence of immunomodulating effects of
doxycycline on systemic cytokine responses in these
patients. Consequently, doxycycline does not seem to be
the optimal treatment of persistent symptoms post-NB.
However, the results need to be confirmed in larger stud-
ies. In addition, studies addressing alternative treatment
approaches for post-treatment symptoms are requested.
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